Profile
Tina Abild Olesen is currently Vice Chairman at World Diabetes Foundation, Managing Director at Novo Nordisk Pharma GmbH, and Director at Embla Medical hf since 2024.
Formerly, Ms. Olesen was Senior Vice President-Global Diabetes Franchise at Novo Nordisk A from 2022 to 2025.
Education includes graduate and MBA degrees from Copenhagen Business School.
Tina Olesen active positions
| Companies | Position | Start |
|---|---|---|
| EMBLA MEDICAL HF. | Director/Board Member | 01/03/2024 |
Novo Nordisk Pharma GmbH
Novo Nordisk Pharma GmbH Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Chief Executive Officer | - |
World Diabetes Foundation
World Diabetes Foundation Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Director/Board Member | - |
Former positions of Tina Olesen
| Companies | Position | End |
|---|---|---|
| NOVO NORDISK A/S | Corporate Officer/Principal | 01/08/2025 |
Training of Tina Olesen
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Novo Nordisk A/S
Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Novo Nordisk Pharma GmbH
Novo Nordisk Pharma GmbH Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Health Technology |
Embla Medical hf
Embla Medical hf Medical SpecialtiesHealth Technology Provides non-invasive orthopedic products and support services | Health Technology |
Copenhagen Business School
Copenhagen Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
World Diabetes Foundation
World Diabetes Foundation Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Miscellaneous |
- Stock Market
- Insiders
- Tina Olesen
















